account for the major causes of morbidity and mortality in diabetic patients. 13 As a transcription factor, KLF11 is expressed ubiquitously and is abundant in adipose tissue, testis, breast, artery, and lung (GTEx database). RNA sequencing data show that the mRNA level of KLF11 is modest in human endothelium and moderate in human aortic smooth muscle cells (HASMCs). 6 Prior studies from others and our group demonstrated that KLF11 plays an important role in maintaining vascular homeostasis. 14, 15 Specifically, KLF11 inhibits endothelial activation in the presence of inflammatory stimuli and functions as a peroxisome proliferator-activated receptor-γ coregulator to attenuate middle cerebral artery occlusion-induced stroke in mice. 16 These in vitro and in vivo observations form the basis of the current view that KLF11 is a vessel protective factor. However, the role of KLF11 in VSMC biology and thrombosis has not been explored.
In the present study, we focused on VSMC KLF11 and, using in vivo VSMC-specific loss-of-function approaches, demonstrated that this factor is an inhibitor of experimental arterial thrombosis through transcriptional repression of tissue factor (TF, encoded by the F3 gene) in VSMCs.
Materials and Methods
The data that support the findings of this study are available from the corresponding author on reasonable request. An extended version of this section is available as Extended Materials and Methods. in the online-only Data Supplement
Animals
Conventional Klf11 knockout mice (Klf11 KO) and wild-type (WT) mice in the C57BL/6J background were previously described The inducible smooth muscle cell-specific Klf11 KO (Sm-Klf11 KO) mice were generated by cross-breeding Klf11 fl/fl mice with Myh11-CreER T2 mice (019079, Jackson Laboratory). 17 The primer sequences for mouse genotyping are shown (Table I in T2 transgene is inserted on the Y chromosome, 18 only male Sm-Cre/Klf11 fl/fl mice can be generated using this approach. All animal care and experimental procedures were approved by the University of Michigan Animal Care and Use Committee.
Ferric Chloride-Induced Carotid Artery Thrombosis Model
Ferric chloride (FeCl 3 )-induced carotid artery thrombosis was conducted as previously described 19 and detailed in the Extended Materials and Methods in the online-only Data Supplement.
Bone Marrow Transplantation
The protocol for syngeneic bone marrow transplantation (BMT) was previously described 20, 21 and detailed in the Extended Materials and Methods in the online-only Data Supplement.
Prothrombin Time and Activated Partial Thromboplastin Time Measurements
Platelet-poor-plasma was collected as previously described 22 and detailed in the Extended Materials and Methods in the online-only Data Supplement.
Tail-Bleeding Assay
Conventional Klf11 KO mice and WT mice (8-10-week-old male) were used in this experiment. As previously described, 23 a transverse incision at the 5 mm distal end of the tail was performed and the tail was immersed in saline at 37°C. Bleeding time was recorded as the time to cessation of bleeding.
Reagents and Antibodies
Reagents and Antibodies are listed in the Extended Materials and Methods in the online-only Data Supplement.
Cell Culture
HASMCs (CC-2571, Lonza) were cultured in smooth muscle growth medium-2 containing 5% FBS (CC-3182, Lonza) and used within 10 passages. Before thrombin stimulation, the HASMCs were made quiescent with DMEM/F12 with 0.5% FBS for 48 hours. A7r5 cells (CRL-1444, ATCC) were cultured in DMEM/ F12 supplemented with 10% FBS) and 50 mg/mL of a penicillin/ streptomycin mix. Mouse aortic smooth muscle cells (MASMCs) were isolated from the conventional Klf11 KO mice and WT mice (3-4-week-old male) as previously described. 17, 24 Details are described in the Extended Materials and Methods in the onlineonly Data Supplement. The purity of MASMCs was validated by immunostaining for α-SMA (α-smooth muscle actin). All cells were cultured in a 5% CO 2 humidified incubator at 37°C. 
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Preparation of Washed Murine Platelets and Platelet Aggregation Assay
The collection of washed murine platelets and platelet aggregation assay were performed as previously described 23 and detailed in the Extended Materials and Methods in the online-only Data Supplement.
Protein Extracts and Western Blot
All protein extractions and Western blots were performed as previously described. 25 
Adenoviral Constructs
Adenoviral vectors overexpressing human KLF11 or LacZ control were generated as previously described. 26 The procedures are detailed in the Extended Materials and Methods in the online-only Data Supplement.
Statistical Analysis
All quantitative data are presented as mean±SEM. Statistical analysis was performed using the GraphPad Prism 7. All data were first subjected to Shapiro-Wilk normality test and F test to evaluate homogeneity of variances. For normally distributed data with similar variances among groups, unpaired Student t test with Welch correction was used for 2-group comparisons and 1-way ANOVA followed by Tukey test was used for >2 groups comparisons. Two-way ANOVA followed by Bonferroni test was applied for comparisons of grouped data under different conditions. Nonparametric Mann-Whitney test was used for data not normally distributed. All results were representative from at least 4 independent experiments.
Results
KLF11 Deficiency Aggravates Arterial Thrombosis In Vivo
To assess the role of KLF11 in arterial thrombosis, we used the conventional Klf11 KO mice previously reported 14 and applied a FeCl 3 -induced thrombosis model for studying arterial thrombosis. 19 The occlusion time in the Klf11 KO male mice was significantly reduced to an average of 62% of that in WT C57BL/6J male mice ( Figure 1A) . A similar prothrombotic phenotype was also observed in Klf11 KO female mice, with the occlusion time reducing to 56% of that in the WT C57BL/6J female mice ( Figure 1B) . To exclude the effects of Klf11 KO in blood cells (such as platelets, neutrophils, and macrophages) in this prothrombotic phenotype, we performed BMT in Klf11 KO and WT mice. The reduced occlusion time in the Klf11 KO group transplanted with WT bone marrow was not rescued when compared with WT mice transplanted with WT bone marrow ( Figure 1C) .
The hemostatic status in the Klf11 KO male mice was evaluated by measuring the function of coagulation factors and platelets. Our results showed that KLF11 did not alter the prothrombin time and activated partial thromboplastin time, which reflect the function of extrinsic/common or intrinsic coagulation pathways, respectively ( Figure 1D-1E) . Bleeding time and thrombin-antithrombin (TAT) complexes were also unchanged in the Klf11 KO mice, indicating that the general hemostatic status was normal in the conventional KLF11-deficient mice ( Figure 1F-1G ). To evaluate whether the deficiency of KLF11 in megakaryocytes can affect the platelet function, we isolated washed platelets and performed thrombin-induced platelet aggregation assay. The maximum platelet aggregation induced by thrombin did not show significant differences between WT and conventional Klf11 KO mice ( Figure II in the online-only Data Supplement).
Smooth Muscle Cell-Specific KLF11 Deficiency Aggravates FeCl 3 -Induced Arterial Thrombosis
Taking into account that the hemostatic status in the circulation was not affected and the BMT cannot rescue the occlusion time in the conventional Klf11 KO mice, the phenotype in Klf11 KO mice might result from molecular changes specific to the vascular wall. To further identify the role of VSMC KLF11 in thrombosis, we generated tamoxifen-inducible Sm-Klf11 KO (Myh11-CreER +Oil) were used as controls. KLF11 deficiency in the aortic media of Sm-Klf11 KO mice was confirmed at the mRNA and protein levels ( Figure  IIIB -IIIC in the online-only Data Supplement). The specificity of the Myh11-CreER T2 in the aorta had been confirmed previously, as no expression was detected in the cells from blood and bone marrow. 27 In the FeCl 3 thrombosis model, Sm-Klf11 KO mice exhibited a similar prothrombotic phenotype as that observed in the conventional Klf11 KO mice. The occlusion time in the Sm-Klf11 KO mice was significantly reduced to an average of 67% of that in the Sm-Cre/Klf11 fl/fl +Oil control mice ( Figure 1H ). Our data suggest that VSMC KLF11 protects against arterial thrombosis.
TF Expression Is Increased in the Vascular Wall of Conventional Klf11 KO Mice
TF is an important initiator of the coagulation cascade, which can generate insoluble fibrins and form a thrombus. The vascular wall TF contributes to arterial thrombosis in cardiovascular diseases, such as atherosclerotic plaque rupture and myocardial infarction. 28 VSMC TF is critical for arterial thrombus formation in the mouse FeCl 3 thrombosis model. 19 To determine whether TF is an effector mediating the enhanced thrombosis resulting from KLF11 deficiency, we measured the expression of TF in the aorta of conventional Klf11 KO mice and WT mice in basal conditions. First, the activity of circulating microvesicle-associated TF showed no significant differences between Klf11 KO and WT mice ( Figure 2A ). We applied anti-mouse TF 1H1 antibody 29 or rat IgG to validate the specificity of this assay. Next, we observed increased F3 mRNA level and TF activity in the isolated carotid artery of conventional Klf11 KO mice ( Figure 2B and 2C). The elevated aortic TF activity can also be blocked by TF 1H1 antibody. Furthermore, the immunofluorescence staining data showed that the TF protein was consistently upregulated in the vascular wall, and colocalized with α-SMA, a specific marker of VSMCs. Moreover, the Klf11 KO mice also showed increased TF expression under lipopolysaccharide-induced inflammatory conditions ( Figure 2D ). The relative TF intensity in the vascular wall was quantified and statistically analyzed. Collectively, our data suggest that KLF11 negatively regulates TF levels in VSMCs in vivo. Similar to the data in Figure 1G , no significant difference in TAT complexes was observed between WT and Klf11 KO mice in basal conditions. However, there were higher TAT complexes in Klf11 KO mice after lipopolysaccharide treatment ( Figure IV in the onlineonly Data Supplement).
KLF11 Overexpression Rescues the TF Upregulation in KLF11-Deficient MASMCs
As a complementary and necessary approach, MASMCs were isolated from male and female conventional Klf11 KO mice and WT mice. The isolated MASMCs were characterized by immunostaining for α-SMA (Figure V in the online-only Data Supplement). The Klf11 deficiency was confirmed by real-time quantitative polymerase chain reaction ( Figure 3A and 3E) . A higher TF expression was observed in the MASMCs from both male and female Klf11 KO mice compared with WT mice ( Figure 3B-3D and 3F-3H, Ad-LacZ [adenovirus-mediated overexpression of LacZ]). In both sexes, restoration of KLF11 can rescue the phenotype in Klf11 KO MASMCs. As expected, the upregulated TF expression was significantly alleviated after KLF11 overexpression, at both mRNA and protein levels ( Figure 3B-3D and 3F-3H, Ad-KLF11 [adenovirus-mediated overexpression of KLF11]). These results indicate that endogenous KLF11 is required to prevent excessive TF upregulation, a hallmark of VSMC involvement in thrombosis.
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KLF11 Inhibits TF Expression in HASMCs
To determine whether KLF11 is essential to regulate TF in VSMCs, we measured TF expression upon KLF11 knockdown in HASMCs. The efficiency of small interfering RNAmediated KLF11 knockdown was confirmed at the mRNA + tamoxifen) mice, were subjected to 10% FeCl 3 to induce thrombosis. Representative images of blood flow detected by ultrasound are shown and the occlusion time in control and Sm-Klf11 KO mice was recorded (n=11/group). **P<0.01 using one-way ANOVA followed by Tukey test.
and protein levels ( Figure 4A ). The KLF11 knockdown in HASMCs increased both the basal and thrombin-induced expression of TF at the mRNA and protein levels ( Figure 4B-4D) . Similar effects were observed in HASMCs stimulated with 10% FBS-containing culture medium ( Figure 4E-4G) .
Apart from TF, other factors can also affect the formation of arterial thrombus. In HASMCs, the expression of other thrombosis related factors, such as tissue factor pathway inhibitor (TFPI) and protease-activated receptor-1 (PAR-1), and inflammatory genes, such as monocyte chemoattractant protein-1 (MCP-1) and interleukin 1 beta (IL-1β) were not significantly changed in the KLF11-deficient HASMCs ( Figure VI in the online-only Data Supplement).
Furthermore, we upregulated KLF11 in primary HASMCs to determine whether KLF11 regulates TF in vitro. In HASMCs, adenovirus-mediated overexpression of KLF11 ( Figure 5A ) significantly inhibited the thrombin-induced TF expression at both mRNA and protein levels ( Figure 5B-5D) . Similarly, KLF11 also suppressed TF expression in HASMCs stimulated with 10% FBS-containing culture medium ( Figure 5E-5G) . Thus, our data suggest that KLF11 potently inhibits TF in human VSMCs under either thrombin stimulation or normal serum conditions. Interestingly, KLF11 overexpression also decreased TNF-α (tumor necrosis factor alpha)-induced TF expression in human umbilical vein endothelial cells (ECs) at both mRNA and protein levels ( Figure VII in the online-only Data Supplement), suggesting that endothelial KLF11 also may have an important role in thrombosis.
KLF11 Inhibits F3 Transcription
Next, we determined the mechanism that mediates the regulation of F3 by KLF11. KLF11 was originally identified as the transforming growth factor-β-inducible early gene 2 (TIEG2), with a preference to bind at GC-rich sequences (GGGTG). 30 Transcription factor binding site analysis of the human F3 gene (Genomatix) revealed a relatively conserved TIEG binding site (-177 to −161 bp) upstream of Data are presented by subtracting the amount of FXa (coagulation factor Xa) generated in the presence of TF 1H1 antibody from the amount of total FXa generated in the presence of IgG. B, F3 mRNA level in carotid arteries from wild-type (WT) and Klf11 knockout (KO) mice. The mRNA level was normalized by 18S and is presented relative to the WT group set as 1 (n=4/group). C, The aortic TF activity was measured and presented as in A, after preincubation with IgG or TF 1H1 antibody and normalized to the total protein quantity (n=6/ group). **P<0.01 using unpaired Student t test (A-C). D, Expression of TF (Alexa 647, displayed in green) and α-SMA (α-smooth muscle actin, Alexa 568, displayed in red) in mouse aorta at basal level or 4 h after lipopolysaccharide (LPS; 30 µg/kg) tail vein injection was visualized by immunofluorescence staining. Respective IgG staining was used as negative control. Scale bars=50 µm. Quantification was performed from 4 mice, randomly selecting 3 different medial regions from each specimen and dividing the TF immunofluorescence intensity by medial area (indicated by α-SMA positive cells). Data are presented relative to the basal level of the WT group set as 1. **P<0.01 using 2-way ANOVA followed by Bonferroni test. DAPI indicates 4',6-diamidino-2-phenylindole.
the F3 transcription start site ( Figure 6A ). The TIEG binding site is conserved among human, mouse, rat, and rabbit ( Figure 6B ). To determine whether this TIEG binding site is a functional KLF11 binding region, we performed chromatin immunoprecipitation assay in the HASMCs infected with Ad-flag-KLF11 (adenovirus overexpressing flag-tagged KLF11) or Ad-LacZ. Our data suggest that KLF11 can bind to the region containing this TIEG binding site ( Figure 6C ). To determine whether KLF11 regulates F3 at the transcriptional level, we generated luciferase reporter constructs, which were under the control of different lengths (−906/+162 and −556/+162) of the human F3 promoter. In A7R5 cells, a rat aortic smooth muscle cell line, transfected with different reporter constructs, KLF11 overexpression significantly reduced the luciferase activity ( Figure 6D ). Next, we deleted the TIEG bind site (−177 to −161) in the F3 promoter-driven luciferase construct. As expected, the deletion of the TIEG binding site significantly attenuated the KLF11 inhibition of F3 promoter-driven luciferase activity ( Figure 6E ) from the reporter plasmid. In conclusion, we identified that KLF11 inhibits F3 expression at the transcription level through direct binding to the F3 promoter ( Figure 6F) .
Discussion
In the current study, we observed an increase of arterial thrombosis in both genetically engineered conventional Klf11 KO mice and VSMC-specific Klf11 KO mice. In cultured HASMCs, we demonstrated that KLF11 inhibits TF expression. Mechanistically, KLF11 directly binds to the F3 promoter region and thereby suppresses the transcription of F3. This study demonstrated a potential role for VSMC KLF11 in arterial thrombosis.
The KLF family modulates cardiovascular activity through regulation of metabolism and inflammation in the cardiovascular system. [4] [5] [6] Endothelial KLF2 and KLF4 have been reported to inhibit thrombus formation by inhibiting the transcription of prothrombotic factors (such as plasminogen activator inhibitor 1 and TF) and increasing the expression of antithrombotic factors (such as thrombomodulin) under inflammatory conditions. 6, [31] [32] [33] We previously identified that KLF11 inhibits endothelial activation 14 and attenuates endothelial dysfunction in the mouse middle brain artery occlusion-induced stroke model. 16 Our current finding that VSMC KLF11 inhibits arterial thrombosis advances the understanding of the protective role of KLF11 in vascular diseases. Population genetics studies identified that mutations in the KLF11 gene are positively associated with type 2 diabetes mellitus. 7 Cardiovascular events are the major causes of death in diabetes mellitus. 34 Our study points to a potentially beneficial effect of KLF11 on cardiovascular complications in diabetic patients. Follow-up studies are warranted to determine the role of VSMC KLF11 in diabetes mellitus associated cardiovascular diseases, such as atherosclerosis, thrombosis, and angiogenesis. 
cells). MASMCs were isolated from male (A-D) and female (E-H) wild-type (WT) or Klf11 knockout (KO) mice.
A and E, Klf11 mRNA level of MASMCs from WT and Klf11 KO mice. The mRNA level was normalized by 18S and is presented relative to the WT group set as 1 (n=4/group). **P<0.01 using unpaired Student t test. B-D and F-H, MASMCs isolated from WT or Klf11 KO mice were infected with Ad-LacZ or Ad-KLF11 (50 MOI). B and F, F3 mRNA level of MASMCs was normalized by 18S and is presented relative to the WT infected with Ad-LacZ group set as 1 (n=4/group). C and G, Representative Western blot of TF protein levels. D and H, Band density from 4 independent Western blots was quantitatively analyzed and normalized against β-actin. The WT infected with Ad-LacZ group was set as 1. **P<0.01 or NS, no significance using 2-way ANOVA followed by Bonferroni test (B, D, F, H) . Ad-KLF11 indicates adenovirus overexpressing KLF11; Ad-LacZ, adenovirus overexpressing LacZ; and MOI, multiplicity of infection.
In this study, we used the FeCl 3 thrombosis model, a widely used mouse arterial thrombosis model, 35 to study the role of KLF11 in the vascular wall in vivo. The penetration of FeCl 3 from the adventitia triggers thrombosis. 36 In this study, we found that conventional Klf11 KO mice were more prothrombotic. The BMT study and the measurement of microvesicleassociated TF activity excluded a potential involvement of KLF11 from blood cells and circulation-derived TF. Similar prothrombotic phenotype was observed in the Sm-Klf11 KO mice, which further demonstrated the antithrombotic effects of KLF11 in the vascular wall under basal conditions. TF is critical in maintaining the balance between hemostasis and thrombosis. 37 VSMCs in human atherosclerotic plaques express high levels of TF. [38] [39] [40] Interestingly, a previous study using low-TF mice demonstrated that the vascular wall derived TF, rather than leukocytes derived TF, is responsible for the macrovascular thrombosis. 41 Therefore, the lower expression of TF in the vascular wall, especially in the VSMCs, can limit the initiation of the TF-dependent coagulation cascade and thus be a potentially protective mechanism from the prolonged occlusion time in vivo. Compared with ECs, VSMCs have a higher constitutive expression of TF and are considered as the primary source of TF in the arterial wall. 42 The expression of TF can be rapidly induced in VSMCs after artery injury 43 and contributes to thrombosis events after plaque rupture. 38, 44 The SM22-driven VSMC-specific TF-deficient mice showed an increase in occlusion time in FeCl 3 -induced arterial thrombosis, indicating a key role of VSMC-derived TF in arterial thrombosis. 19 Although TF is not the only key factor in thrombosis formation, inhibition of TF activity by a monoclonal antibody 45 or administration of its counterpart recombinant TFPI 46 showed beneficial effects, which make inhibition of TF a potential pharmaceutical target for thrombosis. In addition, it has been reported that the deficiency of TFPI in smooth muscle cells can reduce the occlusion time in FeCl 3 model. 47 However, in this study, we found that TFPI expression was not significantly changed in the KLF11-deficient VSMCs. Therefore, the increased TF can at least partially account for the prothrombotic phenotype in the KLF11-deficient VSMCs.
It is well known that thrombin causes positive feedback effects on the coagulation cascade, including promoting the contact activation pathway. 48 However, numerous studies indicated that thrombin can also induce TF expression in VSMCs. [49] [50] [51] [52] Thrombin can bind to PAR (protease-activated receptors) on human aortic SMCs and activate PKB (protein kinase B), PKC (protein kinase C), and MAPK (mitogenactivated protein kinase) pathways, which could induce TF expression. [53] [54] [55] Our data demonstrated that KLF11 directly binds to the F3 promoter and inhibits its activity in VSMCs, which account for the KLF11-dependent decreased F3 transcription under thrombin stimulation. The effect of KLF11 on HASMCs were transfected with si-Control or si-KLF11 (40 nmol/L) and 24 h later serum starved with 0.5% FBS for 48 h. Three days after transfection, HASMCs were exposed to thrombin (3.24 µg/mL; B-D) or 10% FBS (E-G) for 4 h. A, The knockdown efficiency of KLF11 was determined by real-time quantitative polymerase chain reaction and Western blot. The mRNA level was normalized by GAPDH and is presented relative to HASMCs transfected with siControl group set as 1 (n=4/group). **P<0.01 using unpaired Student t-test. B and E, F3 mRNA level of HASMCs was normalized by GAPDH and is presented relative to HASMCs transfected with si-Control group set as 1 (n=4/group). C and F, Representative Western blot showing the protein level of TF. D and G, Band density from 4 independent Western blots was quantitatively analyzed and normalized against GAPDH. HASMCs transfected with si-Control group was set as 1. *P<0.05, **P<0.01 using two-way ANOVA followed by Bonferroni test (B, D, E, G) . si-Control indicates nontargeting small interfering RNA control; and si-KLF11, small interfering RNA targeting KLF11.
thrombin-activated signaling pathways (such as PARs, PKB, PKC, and MAPK) warrants future investigation.
In the present study, we demonstrated that KLF11 binds to the F3 promoter to inhibit its transcription ( Figure 6 ). In basal conditions (serum starvation), TF is expressed at low level in VSMCs, and endogenous KLF11 is abundant enough to maintain the low level of TF by direct binding to the F3 promoter. Thus, overexpression of KLF11 did not further inhibit F3 transcription ( Figure 5 ). The chromatin immunoprecipitation ( Figure 6C ) and luciferase ( Figure 6D-6E ) experiments were performed in normal growth conditions (10% FBS). Under these conditions, we observed the inhibitory effect of KLF11 on F3 transcription ( Figure 5) . On thrombin or serum stimulation, overexpressed KLF11 may compete with other transcription factors, such as AP-1 (activator protein-1), 56 whose binding region (−172 to 160 bp) at the F3 promoter overlaps with the KLF11 binding region (−177 to 161 bp). However, KLF11 deficiency may vacate the KLF11 binding site and abolish the repressive effect of KLF11 on the F3 promoter activity. Therefore, KLF11 deficiency can increase F3 transcription even under basal conditions (Figure 4) . The FeCl 3 model is a commonly used experimental model to study arterial thrombosis. 57 However, whether the endothelium is denudated and the internal elastic lamina is intact in this model are still controversial. 58, 59 The mechanisms mediating the VSMC-derived effect on arterial thrombosis in the FeCl 3 model remain to be investigated. Noteworthy, despite an intact internal elastic lamina upon FeCl 3 infiltration, 58, 59 VSMC-specific TF knockout inhibited the thrombus formation in the FeCl 3 model. 19 In the present study, we found that smooth muscle cell-specific Klf11 KO mice had a prothrombotic phenotype in association with increased TF, indicating that VSMC KLF11 can maintain the antithrombotic state through transcriptional control of F3. We also found that KLF11 overexpression potently inhibited TNF-α-induced TF expression in human umbilical vein ECs at both the mRNA and protein levels (Figure VII in the online-only Data Supplement), although it should be highlighted that endogenous levels of KLF11 in ECs are low. 6 Because the contribution of endothelium is unclear in the FeCl 3 model, 58, 59 the function of EC KLF11 in thrombosis warrants further investigation independently in other appropriate thrombosis models.
Interestingly, although there was no significant difference in TAT complexes between WT and Klf11 KO mice in basal conditions, there were higher TAT complexes in Klf11 KO mice after lipopolysaccharide treatment ( Figure 1G and Figure IV in the online-only Data Supplement). In basal conditions, TF is constitutively expressed in the vascular wall and expressed at a lower level in circulation. 60, 61 After lipopolysaccharide stimulation, TF expression is significantly induced not only in vascular wall but also monocytes. 62, 63 We have demonstrated that KLF11 inhibits TF expression in VSMCs and ECs (Figures 3-5 and Figure VII in the online-only Data Supplement). Whether KLF11 also has inhibitory effects on TF expression in monocytes and thereby inhibits the prothrombotic status under lipopolysaccharide treatment warrants future investigation. Moreover, the conversion of prothrombin to thrombin is the common pathway in the coagulation cascade. 61 Under lipopolysaccharide treatment, apart from the increased TF expression, the abnormality of other coagulation factors may also contribute to the elevated TAT complexes in the Klf11 KO mice.
In summary, utilizing gain-and loss-of-function strategies, we demonstrated an important homeostatic role of KLF11 as an antithrombotic factor in the vascular wall. We uncovered KLF11-dependent transcriptional inhibition of F3 in VSMCs as the potential mechanism underlying this antithrombotic effect. Our findings extend the current understanding of the roles of KLF11 in the vascular system. Manipulation of this novel molecular target could contribute to therapeutic strategies aimed at controlling thrombosis under pathological conditions and diabetic vascular pathologies at large. 
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